Trials / Terminated
TerminatedNCT02685046
Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy
Targeted Therapy With Imatinib for Treatment of Poor Prognosis Mesenchymal-type Resectable Colon Cancer: a Proof-of-concept Study in the Preoperative Window Period.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- UMC Utrecht · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this proof-of-concept trial the investigators will study the effects of imatinib treatment on the biology of mesenchymal-type colon cancers.
Detailed description
Tumor biopsies from patients with newly diagnosed colon cancer will be pre-screened with an RT-qPCR test to identify tumors of the mesenchymal subtype. Patients with mesenchymal-type tumors that meet the in- and exclusion criteria will be treated with imatinib during the "window period" that normally precedes surgery. Immediately following tumor resection, biopsies will be taken from the surgical specimen. Gene and protein expression of the pre- and post-treatments biopsies will be compared to assess the effects of imatinib therapy on PDGFR- and cKIT-signalling and on the mesenchymal gene expression profile.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib | Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection. |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2019-09-01
- Completion
- 2019-09-01
- First posted
- 2016-02-18
- Last updated
- 2019-10-14
Locations
3 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02685046. Inclusion in this directory is not an endorsement.